Fokienol is a relatively obscure sesquiterpene alcohol most strongly associated with Siam wood and several sesquiterpene-rich essential oils rather than with a large standalone pharmacology literature. The live evidence base is strongest for identity, structure, and repeated GC-based occurrence, including high levels in Fokienia hodginsii oil and notable levels in some Dittrichia and Hirtellina oils. Direct constituent-specific mechanism or human safety data were not verified, so this profile is best treated as a chemistry-and-occurrence record with cautiously labeled mixture-level bioactivity context.
Chemical identity and composition
PubChem lists fokienol as CID 5352449 with formula C17H28O and IUPAC name (6E,11E)-3,7,13-trimethyltetradeca-1,6,11,13-tetraen-3-ol. Structurally it is a highly unsaturated sesquiterpene alcohol and is commonly discussed alongside trans-nerolidol in sesquiterpene-alcohol-rich oils. In the archive's Siam wood record, fokienol is a leading constituent at 23.46% in one current COA and 37.99% in a supplier chemistry summary, making it one of the clearest identity markers for this oil profile.
Aroma and practical use
- Use the recorded woody, balsamic, soft, sesquiterpenic descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2019 Fitoterapia paper reported Hirtellina lobelii essential oil composed largely of oxygenated sesquiterpenes, including fokienol at 12.0%; the oil showed bactericidal and fungicidal activity, but the authors highlighted alpha-bisabolol rather than fokienol as the major activity lead.
A 2019 Fitoterapia paper reported Hirtellina lobelii essential oil composed largely of oxygenated sesquiterpenes, including fokienol at 12.0%; the oil showed bactericidal and fungicidal activity, but the authors highlighted alpha-bisabolol rather than fokienol as the major activity lead.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2021 Molecules paper on Oxytropis pseudoglandulosa reported fokienol at 11.46% in the volatile oil while the plant extract showed antioxidant and antimicrobial activity; this provides occurrence context but not isolated fokienol testing.
A 2021 Molecules paper on Oxytropis pseudoglandulosa reported fokienol at 11.46% in the volatile oil while the plant extract showed antioxidant and antimicrobial activity; this provides occurrence context but not isolated fokienol testing.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A Jordan Journal of Chemistry paper identified fokienol as the top constituent of Dittrichia viscosa oil at 20.87%, supporting that the molecule can dominate some non-Siam-wood sesquiterpene-rich oil profiles as well.
A Jordan Journal of Chemistry paper identified fokienol as the top constituent of Dittrichia viscosa oil at 20.87%, supporting that the molecule can dominate some non-Siam-wood sesquiterpene-rich oil profiles as well.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Within the archive's Siam wood profile, fokienol is directly quantified between 23.46% and 37.99% across current cited sources, confirming that it is a principal rather than incidental constituent.
Within the archive's Siam wood profile, fokienol is directly quantified between 23.46% and 37.99% across current cited sources, confirming that it is a principal rather than incidental constituent.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific IFRA restriction, dermal maximum, or human tolerability study was verified for isolated fokienol in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the located biological evidence comes from mixed oils and extracts rather than purified fokienol dose-response studies, consumer-facing copy should avoid direct antimicrobial or antioxidant claims for the isolated molecule.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
no validated isolated mechanism verified
No direct human-validated mechanism or clean isolated-molecule pharmacology for fokienol was verified in the reviewed public literature.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical evidence for isolated fokienol was located.
- Direct constituent-specific mechanism work appears sparse; the accessible literature mainly documents occurrence inside complex oils.
- No IFRA Standard exists for fokienol; the previously recorded sensitizing:true and dermal_limit_pct:20 values were not corroborated by any primary source found in this pass and should be treated as unverified placeholders pending better data.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Some findings lack a directly linked source; treat those entries as unverified research notes.